Valuations remain elevated even after a marginal cooldown — Nifty50 trades at 18.4x forward PE, with Pharma the priciest large-cap bet at 33.8x and IT re-rating sharply to 17.3x. On earnings, Nifty50 Q1FY27 EPS grew a strong 12.9% YoY, well ahead of the 4.5% estimate, led by broad-based strength across mid and small caps. Venkatesh Balasubramaniam, MD & Head of Research at JM Financial Institutional Securities, joins us to decode the sector-wise valuation picture and share fresh stock calls — HAL and BEL valuations still look attractive, MTAR Technologies gets initiated with a large BUY, and Data Patterns is also a BUY. He explains why banks aren't a rush-to-buy yet, and why the focus should stay on domestic earnings visibility across infra, auto and consumer names.
According to primary filings and dispatches highlighted by Moneycontrol, the latest move impacts key counters including relevant market segments. Market analysts note that volume activity and corporate disclosures indicate significant retail and domestic institutional engagement with the development.
Terminal indicators suggest a balanced risk-reward profile, with institutional participants waiting for confirmation from subsequent quarterly prints or macro cues. Range-bound consolidation is expected in the near term as market participants digest the broader ramifications of the announcement.
Investors and intraday participants are advised to monitor official exchange disclosures on BSE and NSE, alongside subsequent management commentary. ZeroLive will continue monitoring real-time order book developments, price action triggers, and regulatory updates as they unfold.